Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:HCM NASDAQ:NTLA NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.42-0.9%$9.44$6.05▼$14.51$483.26M1.74757,386 shs519,430 shsHCMHUTCHMED$10.49-3.1%$12.92$10.40▼$19.50$1.89B0.2660,650 shs37,185 shsNTLAIntellia Therapeutics$14.55-2.5%$13.66$7.95▼$28.25$2.08B1.925.68 million shs8.65 million shsTRVITrevi Therapeutics$15.40+5.0%$14.09$5.41▼$16.12$2.08B1.04968,737 shs3.43 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-1.19%+4.76%-17.51%-37.64%+1.35%HCMHUTCHMED-1.19%-0.18%-13.43%-24.27%-35.92%NTLAIntellia Therapeutics+23.20%+10.60%+9.14%+10.68%+79.54%TRVITrevi Therapeutics+3.17%+8.59%+3.24%+31.01%+140.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.42-0.9%$9.44$6.05▼$14.51$483.26M1.74757,386 shs519,430 shsHCMHUTCHMED$10.49-3.1%$12.92$10.40▼$19.50$1.89B0.2660,650 shs37,185 shsNTLAIntellia Therapeutics$14.55-2.5%$13.66$7.95▼$28.25$2.08B1.925.68 million shs8.65 million shsTRVITrevi Therapeutics$15.40+5.0%$14.09$5.41▼$16.12$2.08B1.04968,737 shs3.43 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-1.19%+4.76%-17.51%-37.64%+1.35%HCMHUTCHMED-1.19%-0.18%-13.43%-24.27%-35.92%NTLAIntellia Therapeutics+23.20%+10.60%+9.14%+10.68%+79.54%TRVITrevi Therapeutics+3.17%+8.59%+3.24%+31.01%+140.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.46Hold$15.42107.77% UpsideHCMHUTCHMED 2.40Hold$16.8060.15% UpsideNTLAIntellia Therapeutics 2.35Hold$20.4640.59% UpsideTRVITrevi Therapeutics 3.00Buy$22.9048.70% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, HCM, TRVI, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$49.006/15/2026NTLAIntellia Therapeutics New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.006/15/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/15/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/15/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.006/15/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$30.006/4/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026ARVNArvinas StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$18.005/28/2026HCMHUTCHMED Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.605/26/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/20/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.00(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M1.82N/AN/A$6.76 per share1.10HCMHUTCHMED$548.51M3.34$2.61 per share4.02$7.17 per share1.46NTLAIntellia Therapeutics$67.67M30.04N/AN/A$5.80 per share2.51TRVITrevi TherapeuticsN/AN/AN/AN/A$1.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$3.32N/AN/AN/A-247.54%-44.38%-28.38%8/5/2026 (Estimated)HCMHUTCHMED$456.91MN/AN/A21.41N/AN/AN/AN/A8/3/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)Latest ARVN, HCM, TRVI, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026ARVNArvinas-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/A3/17/2026Q4 2025TRVITrevi Therapeutics-$0.10-$0.06+$0.04-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.445.44HCMHUTCHMED0.054.964.83NTLAIntellia TherapeuticsN/A6.106.10TRVITrevi TherapeuticsN/A24.7524.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%HCMHUTCHMED8.82%NTLAIntellia Therapeutics88.77%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipARVNArvinas7.30%HCMHUTCHMED3.60%NTLAIntellia Therapeutics3.50%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million59.81 millionOptionableHCMHUTCHMED1,796174.47 million168.19 millionNot OptionableNTLAIntellia Therapeutics600139.72 million134.83 millionOptionableTRVITrevi Therapeutics20141.98 million116.00 millionOptionableARVN, HCM, TRVI, and NTLA HeadlinesRecent News About These CompaniesTrevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.June 4, 2026 | aol.comATrevi Therapeutics Shareholders Approve Stock and Governance ChangesJune 4, 2026 | tipranks.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day - SlideshowMay 15, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comTrevi Therapeutics (TRVI) Gets a Buy from H.C. WainwrightMay 8, 2026 | theglobeandmail.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day TranscriptMay 7, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comWhy Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030May 6, 2026 | finance.yahoo.comTrevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5, 2026 | globenewswire.comTrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceApril 30, 2026 | globenewswire.comTrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026April 28, 2026 | globenewswire.comDid Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?April 24, 2026 | finance.yahoo.comTrevi Therapeutics to Participate in Upcoming May EventsApril 23, 2026 | globenewswire.comTrevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesApril 20, 2026 | globenewswire.comWhat's going on with Trevi Therapeutics stock?April 17, 2026 | msn.comTRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happeningApril 17, 2026 | msn.comTrevi Therapeutics: Late-Stage Transition Meets Execution RiskApril 17, 2026 | seekingalpha.comTrevi Therapeutics Prices Public Offering to Fund HaduvioApril 17, 2026 | tipranks.comTrevi Therapeutics, Inc. Prices Underwritten Public Offering of 11.6 Million Shares at $13.00 EachApril 16, 2026 | quiverquant.comQMarketBeat’s Top 5 Rated Small-Cap Stocks...December 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, HCM, TRVI, and NTLA Company DescriptionsArvinas NASDAQ:ARVN$7.42 -0.07 (-0.93%) Closing price 04:00 PM EasternExtended Trading$7.42 0.00 (0.00%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.HUTCHMED NASDAQ:HCM$10.49 -0.34 (-3.14%) Closing price 04:00 PM EasternExtended Trading$10.48 -0.01 (-0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Intellia Therapeutics NASDAQ:NTLA$14.55 -0.37 (-2.48%) Closing price 04:00 PM EasternExtended Trading$14.38 -0.17 (-1.15%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Trevi Therapeutics NASDAQ:TRVI$15.40 +0.74 (+5.05%) Closing price 04:00 PM EasternExtended Trading$15.40 +0.00 (+0.01%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
